HPV Positive Oropharyngeal Squamous Cell Carcinoma Clinical Trial
Official title:
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
This research is being conducted to understand if treatment can be tailored for participants with HPV-related oropharynx cancers using both clinical features (stage of the tumor, smoking status) combined with an investigational HPV blood test. The names of the test and treatments involved in this study are: - NavDx® HPV ctDNA testing (HPV blood test) - Radiation therapy - Chemotherapy: Cisplatin, or Carboplatin and Paclitaxel (not all participants receive any or all of these agents)
This research study involves HPV DNA testing (a blood test that measures the levels of DNA from the human papillomavirus in the bloodstream which investigator think sheds from the cancer itself), radiation therapy, and chemotherapy for some participants. The research study procedures includes: screening for eligibility, and study treatments including evaluations and follow-up visits. The names of the test and treatments involved in this study are: - NavDx® HPV ctDNA testing (HPV blood test) - Radiation therapy: Radiation therapy alone or combined with chemotherapy is considered a standard treatment for this disease. The investigators are researching the effectiveness of reducing the radiation doses and, in some cases, also reducing the chemotherapy dose for certain participants with favorable clinical characteristics and with certain HPV blood test results. - Chemotherapy: Cisplatin, or Carboplatin and Paclitaxel (not all participants receive any or all of these agents) - Study treatment will for up to 7 weeks and participants will be followed for 5 years from the beginning of the study. - It is expected that about 75 people will take part in this research study. The HPV ctDNA levels will be measured using a blood test called NavDx®, which will be provided free of charge from the company NAVERIS. ctDNA testing refers to circulating tumor (ct)DNA or measuring DNA fragments floating in the bloodstream that are released from the cancer cells. This testing has shown promise in early detection of cancer recurrence in several solid tumor types (including colorectal, urothelial, and breast cancer). Additionally, recent studies have shown a connection between baseline ctDNA levels and disease risk. The U.S. Food and Drug Administration (FDA) has not approved NavDx® as a method for guiding treatment decision-making, but this is an important part of this research study. While the NavDx® assay is investigational, it is performed in a Clinical Laboratory Improvement Amendment (CLIA) certified clinical laboratory and is currently available as a clinical tool for measuring HPV ctDNA levels in some cancer patients. CLIA regulations include federal standards applicable to all United States facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. Radiation therapy alone or combined with chemotherapy is considered a standard treatment for this disease. The investigators are researching the effectiveness of reducing the radiation doses and, in some cases, also reducing the chemotherapy dose for certain participants with favorable clinical characteristics and with certain HPV blood test results. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02113878 -
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
|
Phase 1 | |
| Recruiting |
NCT04444869 -
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
|
Phase 2 | |
| Withdrawn |
NCT04001413 -
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT05524025 -
The SPOT-HPV Study
|
||
| Recruiting |
NCT05600842 -
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
|
||
| Recruiting |
NCT05973487 -
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
|
Phase 1 | |
| Terminated |
NCT05061940 -
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
|
||
| Recruiting |
NCT05119036 -
Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06088381 -
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
|
Phase 2 | |
| Recruiting |
NCT05686226 -
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
|
Phase 2 | |
| Recruiting |
NCT05814549 -
A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
|
||
| Active, not recruiting |
NCT04260126 -
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
|
Phase 2 | |
| Recruiting |
NCT05108870 -
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05307939 -
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
|
Phase 2 | |
| Active, not recruiting |
NCT04871490 -
Improving Detection and Early Action for HPV-positive Oropharynx Cancer
|
N/A | |
| Not yet recruiting |
NCT06319963 -
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT03601507 -
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01855451 -
Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
|
Phase 3 | |
| Terminated |
NCT04301011 -
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05639972 -
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
|
Phase 1/Phase 2 |